- Home
- ATLN vs CMPX Comparison
ATLN vs CMPX Comparison
Compare ATLN & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLN
- CMPX
- Stock Information
- Founded
- ATLN 2014
- CMPX 2014
- Country
- ATLN United States
- CMPX United States
- Employees
- ATLN N/A
- CMPX N/A
- Industry
- ATLN
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- ATLN
- CMPX Health Care
- Exchange
- ATLN NYSE
- CMPX Nasdaq
- Market Cap
- ATLN 194.7M
- CMPX 291.8M
- IPO Year
- ATLN 2021
- CMPX N/A
- Fundamental
- Price
- ATLN $2.51
- CMPX $2.15
- Analyst Decision
- ATLN
- CMPX Strong Buy
- Analyst Count
- ATLN 0
- CMPX 8
- Target Price
- ATLN N/A
- CMPX $13.13
- AVG Volume (30 Days)
- ATLN 32.2K
- CMPX 790.1K
- Earning Date
- ATLN 05-14-2025
- CMPX 05-08-2025
- Dividend Yield
- ATLN N/A
- CMPX N/A
- EPS Growth
- ATLN N/A
- CMPX N/A
- EPS
- ATLN N/A
- CMPX N/A
- Revenue
- ATLN $444,795,409.00
- CMPX $850,000.00
- Revenue This Year
- ATLN N/A
- CMPX N/A
- Revenue Next Year
- ATLN N/A
- CMPX N/A
- P/E Ratio
- ATLN N/A
- CMPX N/A
- Revenue Growth
- ATLN 10.11
- CMPX N/A
- 52 Week Low
- ATLN $1.90
- CMPX $0.77
- 52 Week High
- ATLN $8.98
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- ATLN N/A
- CMPX 60.21
- Support Level
- ATLN N/A
- CMPX $2.06
- Resistance Level
- ATLN N/A
- CMPX $2.23
- Average True Range (ATR)
- ATLN 0.00
- CMPX 0.12
- MACD
- ATLN 0.00
- CMPX 0.01
- Stochastic Oscillator
- ATLN 0.00
- CMPX 73.81
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp is a U.S.-based outsourced services and workforce solutions company. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information technology, legal, light industrial, and medical fields. It also provides productivity consulting and workforce management solutions.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.